Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, announced it will release its third-quarter 2024 financial results on Thursday, November 7, 2024. The company will host a conference call and webcast at 8:30 a.m. (ET) to discuss financial results and business highlights. The event will include presentation slides and will be accessible through the company's Investor Relations website. A replay will be available until November 7, 2025.
Vericel (NASDAQ:VCEL), un leader nelle terapie avanzate per la medicina sportiva e la cura delle ustioni gravi, ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 giovedì 7 novembre 2024. L'azienda ospiterà una teleconferenza e un webcast alle 8:30 (ET) per discutere i risultati finanziari e i punti salienti aziendali. L'evento includerà diapositive di presentazione e sarà accessibile attraverso il sito web delle relazioni con gli investitori dell'azienda. Una registrazione sarà disponibile fino al 7 novembre 2025.
Vericel (NASDAQ:VCEL), un líder en terapias avanzadas para medicina deportiva y cuidados de quemaduras severas, anunció que publicará sus resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre de 2024. La empresa llevará a cabo una llamada y webcast a las 8:30 a.m. (ET) para discutir los resultados financieros y los aspectos más destacados del negocio. El evento incluirá diapositivas de presentación y será accesible a través del sitio web de Relaciones con Inversores de la empresa. Una repetición estará disponible hasta el 7 de noviembre de 2025.
Vericel (NASDAQ:VCEL)는 스포츠 의학과 심각한 화상 치료를 위한 고급 치료법의 선두주자로, 2024년 11월 7일 목요일에 2024년 3분기 재무 결과를 발표한다고 발표했습니다. 회사는 8:30 a.m. (ET)에 재무 결과 및 비즈니스 하이라이트에 대해 논의하기 위해 컨퍼런스 콜 및 웹캐스트를 진행할 것입니다. 행사에서는 프레젠테이션 슬라이드가 포함되며, 회사의 투자자 관계 웹사이트를 통해 접근할 수 있습니다. 재생은 2025년 11월 7일까지 가능합니다.
Vericel (NASDAQ:VCEL), un leader dans les thérapies avancées pour la médecine sportive et les soins des brûlures graves, a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le jeudi 7 novembre 2024. L'entreprise organisera une conférence téléphonique et un webinaire à 8h30 (ET) pour discuter des résultats financiers et des points forts de l'entreprise. L'événement comprendra des diapositives de présentation et sera accessible via le site web des Relations Investisseurs de l'entreprise. Un enregistrement sera disponible jusqu'au 7 novembre 2025.
Vericel (NASDAQ:VCEL), ein führendes Unternehmen für fortgeschrittene Therapien in der Sportmedizin und bei schweren Brandverletzungen, gab bekannt, dass es am Donnerstag, den 7. November 2024, seine Finanzergebnisse für das dritte Quartal 2024 veröffentlichen wird. Das Unternehmen wird um 8:30 Uhr (ET) eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse und die Geschäftshöhepunkte zu besprechen. Die Veranstaltung wird Präsentationsfolien enthalten und über die Investor-Relations-Website des Unternehmens zugänglich sein. Eine Wiederholung wird bis zum 7. November 2025 verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.
To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until November 7, 2025.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
Media Contact:
Julie Downs
media@vcel.com
FAQ
When will Vericel (VCEL) report Q3 2024 earnings?
What time is Vericel's (VCEL) Q3 2024 earnings call?
How can I access Vericel's (VCEL) Q3 2024 earnings webcast?
How long will Vericel's (VCEL) Q3 2024 earnings call replay be available?
